Company intelligence / Profile preview
Afimmune
Dublin, Leinster, Irelandafimmune.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
Afimmune is a Dublin-based clinical-stage biotech focused on developing novel therapeutics—primarily small molecule bioactive lipids—for rare and inflammatory diseases. Its lead candidate, Epeleuton, targets sickle cell disease and has shown promising preclinical efficacy with ongoing Phase 2 trials in North America. The company has received orphan drug designation from the FDA for Epeleuton in SCD. Other pipeline assets are at earlier stages of development or have been discontinued for non-core indications such as diabetes mellitus type II.
- Therapeutic areas
- HematologyImmunologyEndocrinology
- Modalities
- small molecules (notably synthetic fatty acids such as Epeleuton)bioactive lipids
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Pathway to Cures (venture philanthropy fund of the American National Bleeding Disorders Foundation)member of SCDAA’s SCD C.A.R.E.S. Consortium
Beyond the preview
Go deeper on Afimmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Afimmune.